Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject
Status:
COMPLETED
Trial end date:
2023-02-15
Target enrollment:
Participant gender:
Summary
A Trial to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics, of Sibeprenlimab Solution Administered Subcutaneously in Chinese Healthy Subjects
Phase:
PHASE1
Details
Lead Sponsor:
Otsuka Beijing Research Institute
Collaborator:
Otsuka Pharmaceutical Development & Commercialization, Inc.